Page last updated: 2024-10-16

gamma-aminobutyric acid and Psychotic Disorders

gamma-aminobutyric acid has been researched along with Psychotic Disorders in 106 studies

gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.

Psychotic Disorders: Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)

Research Excerpts

ExcerptRelevanceReference
" Gabapentin is a relatively new anticonvulsant being investigated for potential use in the treatment of bipolar disorder (BD), anxiety disorders, behavioral dyscontrol, and substance use disorders."8.80Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. ( Letterman, L; Markowitz, JS, 1999)
"Abnormal glutamate and GABA (gamma-aminobutyric acid) levels have been found in the early phase of schizophrenia and may underlie cognitive deficits."8.02Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naïve Patients With Schizophrenia or Psychosis. ( Andersen, GS; Bojesen, KB; Broberg, BV; Edden, RAE; Fagerlund, B; Glenthøj, BY; Jessen, K; Larsson, HBW; Nielsen, MØ; Rostrup, E; Sigvard, A; Tangmose, K; Thomas, MB, 2021)
"In total, 56 antipsychotic-naïve patients with schizophrenia or psychotic disorder and 51 healthy control subjects underwent magnetic resonance spectroscopy to measure glutamate, glutamate+glutamine (Glx), and GABA levels in dorsal anterior cingulate cortex (ACC) and glutamate and Glx levels in left thalamus."8.02Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naïve Patients With Schizophrenia or Psychosis. ( Andersen, GS; Bojesen, KB; Broberg, BV; Edden, RAE; Fagerlund, B; Glenthøj, BY; Jessen, K; Larsson, HBW; Nielsen, MØ; Rostrup, E; Sigvard, A; Tangmose, K; Thomas, MB, 2021)
"Gabapentin is a relatively new anticonvulsant being investigated for potential use in the treatment of bipolar disorder (BD), anxiety disorders, behavioral dyscontrol, and substance use disorders."6.40Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. ( Letterman, L; Markowitz, JS, 1999)
"Schizophrenia is accompanied by impaired cortical inhibition, as measured by several markers including the cortical silent period (CSP)."5.46Risperidone increases the cortical silent period in drug-naive patients with first-episode schizophrenia: A transcranial magnetic stimulation study. ( Ceskova, E; Hublova, V; Kasparek, T; Mayerova, M; Prikrylova Kucerova, H; Ustohal, L, 2017)
"Abnormalities of GABAergic (gamma-aminobutyric acidergic) systems may play a role in schizophrenia and mood disorders."5.41Medial Frontal Cortex GABA Concentrations in Psychosis Spectrum and Mood Disorders: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies. ( Simmonite, M; Steeby, CJ; Taylor, SF, 2023)
"Ten patients with refractory partial epilepsy, previous mental retardation and psychosis or other significant psychiatric morbidity treated with vigabatrin were submitted periodically to specific tests (to quantify any possible change in behavioural parameters) and also to EEG recordings."5.09Vigabatrin use in psychotic epileptic patients: report of a prospective pilot study. ( Baldi, PL; De Agostini, G; Ferrari Ginevra, O; Lanzi, G; Muzio, C; Termine, C; Veggiotti, P, 1999)
"We review our current understanding of abnormal γ band oscillations in schizophrenia, their association with symptoms and the underlying cortical circuit abnormality, with a particular focus on the role of fast-spiking parvalbumin gamma-aminobutyric acid (GABA) neurons in the disease state."4.93Gamma band oscillations: a key to understanding schizophrenia symptoms and neural circuit abnormalities. ( McCarley, RW; McNally, JM, 2016)
" Gabapentin is a relatively new anticonvulsant being investigated for potential use in the treatment of bipolar disorder (BD), anxiety disorders, behavioral dyscontrol, and substance use disorders."4.80Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. ( Letterman, L; Markowitz, JS, 1999)
"Abnormal glutamate and GABA (gamma-aminobutyric acid) levels have been found in the early phase of schizophrenia and may underlie cognitive deficits."4.02Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naïve Patients With Schizophrenia or Psychosis. ( Andersen, GS; Bojesen, KB; Broberg, BV; Edden, RAE; Fagerlund, B; Glenthøj, BY; Jessen, K; Larsson, HBW; Nielsen, MØ; Rostrup, E; Sigvard, A; Tangmose, K; Thomas, MB, 2021)
"In total, 56 antipsychotic-naïve patients with schizophrenia or psychotic disorder and 51 healthy control subjects underwent magnetic resonance spectroscopy to measure glutamate, glutamate+glutamine (Glx), and GABA levels in dorsal anterior cingulate cortex (ACC) and glutamate and Glx levels in left thalamus."4.02Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naïve Patients With Schizophrenia or Psychosis. ( Andersen, GS; Bojesen, KB; Broberg, BV; Edden, RAE; Fagerlund, B; Glenthøj, BY; Jessen, K; Larsson, HBW; Nielsen, MØ; Rostrup, E; Sigvard, A; Tangmose, K; Thomas, MB, 2021)
"Psychotic disorders, such as schizophrenia, are characterized by prevalent and persistent executive deficits that are believed to be the result of dysfunctional inhibitory gamma-aminobutyric acid (GABA) processing of the prefrontal cortex (PFC)."3.83GABAergic mRNA expression is differentially expressed across the prelimbic and orbitofrontal cortices of rats sensitized to methamphetamine: Relevance to psychosis. ( Cornish, JL; Franklin, JL; Goodchild, AK; Parker, LM; Wearne, TA, 2016)
"The authors measured gamma-aminobutyric acid (GABA) levels in the lumbar CSF of patients with depression, with psychosis, or undergoing evaluation for a neurologic disorder."3.66GABA levels in CSF of patients with psychiatric disorders. ( Bowers, MB; Gold, BI; Roth, RH; Sweeney, DW, 1980)
"Gabapentin was effective in the treatment of mania and hypomania in patients with bipolar and schizoaffective disorders."2.69Clinical experience with gabapentin in patients with bipolar or schizoaffective disorder: results of an open-label study. ( Cabras, PL; Carta, MG; Hardoy, MC; Hardoy, MJ, 1999)
"In DSM-5, catatonia syndrome may be diagnosed as a specifier to major mood disorders, psychotic disorders, general medical conditions, and as catatonia not otherwise specified."2.53Catatonia. ( Strik, W; Walther, S, 2016)
"Catatonia is potentially life threatening."2.53Catatonia. ( Strik, W; Walther, S, 2016)
"Brief postictal and alternating psychoses provide an opportunity to understand the complex relationships between epilepsy and schizophrenia-like brief psychotic episodes, and this understanding can assist in their management."2.44Alternating and postictal psychoses: review and a unifying hypothesis. ( Sachdev, PS, 2007)
"After adolescence, recurrent affective psychoses are relatively frequent, especially in patients with uniparental disomy."2.43Prader-Willi syndrome: atypical psychoses and motor dysfunctions. ( Tuinier, S; Verhoeven, WM, 2006)
"Differences between autism and catatonia of age-of-onset, symptoms, and illness course, do not exclude a common genetic etiology."2.42Autism as early expression of catatonia. ( Dhossche, DM, 2004)
"Reports indicate that catatonia often occurs in autism."2.42Autism as early expression of catatonia. ( Dhossche, DM, 2004)
"Several areas of overlap between autism and catatonia are found."2.42Autism as early expression of catatonia. ( Dhossche, DM, 2004)
"The literature on autism and catatonia are reviewed to identify areas of overlap."2.42Autism as early expression of catatonia. ( Dhossche, DM, 2004)
"Modern classificatory schemes define autism and catatonia separately and are not conducive to study areas of overlap."2.42Autism as early expression of catatonia. ( Dhossche, DM, 2004)
"Gabapentin is a relatively new anticonvulsant being investigated for potential use in the treatment of bipolar disorder (BD), anxiety disorders, behavioral dyscontrol, and substance use disorders."2.40Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. ( Letterman, L; Markowitz, JS, 1999)
"Schizophrenia is the most prevalent form of psychosis, but this may also occur due to other medical conditions (e."2.40GABA-ergic neurons and the neurobiology of schizophrenia and other psychoses. ( Keverne, EB, 1999)
"Schizophrenia is one of the most common and perhaps the most disabling of mental disorders, for which effective forms of treatment have not yet been established definitively."2.40Schizophrenia, psychosis, and the basal ganglia. ( Busatto, GF; Kerwin, RW, 1997)
"The underlying mechanisms of autism and schizophrenia are poorly understood, partly due to a lack of dimension-specific research."1.51The association of excitation and inhibition signaling with the relative symptom expression of autism and psychosis-proneness: Implications for psychopharmacology. ( Abu-Akel, A; Crewther, DP; Ford, TC, 2019)
"Stigmasterol treated animals showed significant decrease in locomotor activity, stereotypic behaviours, immobility duration and increased step down latency."1.48Protective effects of stigmasterol against ketamine-induced psychotic symptoms: Possible behavioral, biochemical and histopathological changes in mice. ( Dhingra, S; Jindal, DK; Parle, M; Yadav, M, 2018)
"Spermidine was significant to alleviate the ketamine-induced psychotic symptoms as indicated by decrease in locomotor activity in actophotometer, stereotypic behaviours, immobility duration in force swim test and latency to climb the pole in pole climb avoidance test."1.48Potential effect of spermidine on GABA, dopamine, acetylcholinesterase, oxidative stress and proinflammatory cytokines to diminish ketamine-induced psychotic symptoms in rats. ( Jindal, DK; Parle, M; Sharma, N; Yadav, M, 2018)
"Spermidine did not produce cataleptic effect on bar test at lower dose, but at the higher dose its cataleptic effect was similar to haloperidol."1.48Potential effect of spermidine on GABA, dopamine, acetylcholinesterase, oxidative stress and proinflammatory cytokines to diminish ketamine-induced psychotic symptoms in rats. ( Jindal, DK; Parle, M; Sharma, N; Yadav, M, 2018)
"Schizophrenia is characterized by a multiplicity of symptoms arising from almost all domains of mental function."1.48CSF GABA is reduced in first-episode psychosis and associates to symptom severity. ( Cervenka, S; Collste, K; Engberg, G; Erhardt, S; Fatouros-Bergman, H; Flyckt, L; Goiny, M; Malmqvist, A; Orhan, F; Piehl, F; Sellgren, CM; Victorsson, P, 2018)
"Gamma-aminobutyric acid levels were obtained from the medial prefrontal cortex using MEGA-PRESS and expressed as peak-area ratios relative to the synchronously acquired creatine signal."1.48Cortical GABA in Subjects at Ultra-High Risk of Psychosis: Relationship to Negative Prodromal Symptoms. ( Allen, P; Azis, M; Bonoldi, I; Bossong, M; Broome, M; Grace, AA; Horder, J; Howes, OD; Lythgoe, DJ; McGuire, P; Modinos, G; Murphy, DG; Perez, J; Simsek, F; Stone, JM, 2018)
"Gallic acid has been reported to possess a number of psychopharmacological activities."1.48Protective effect of gallic acid in experimental model of ketamine-induced psychosis: possible behaviour, biochemical, neurochemical and cellular alterations. ( Dhingra, MS; Dhingra, S; Jindal, DK; Kumar, A; Parle, M; Yadav, M, 2018)
"Schizophrenia is accompanied by impaired cortical inhibition, as measured by several markers including the cortical silent period (CSP)."1.46Risperidone increases the cortical silent period in drug-naive patients with first-episode schizophrenia: A transcranial magnetic stimulation study. ( Ceskova, E; Hublova, V; Kasparek, T; Mayerova, M; Prikrylova Kucerova, H; Ustohal, L, 2017)
" Antipsychotic dosage was negatively correlated with GABA+ levels, but the on-off medication studies indicated no difference in GABA+ levels on antipsychotics compared with off antipsychotics."1.43Prefrontal GABA Levels Measured With Magnetic Resonance Spectroscopy in Patients With Psychosis and Unaffected Siblings. ( Apud, JA; Barnett, AS; Berman, KF; DeJong, K; Dickinson, D; Kuo, S; Marenco, S; Meyer, C; Shen, J; van der Veen, JW; Weinberger, DR, 2016)
"Schizophrenia is a neurodevelopmental disorder with altered expression of GABA-related genes in the prefrontal cortex (PFC)."1.42Altered cortical expression of GABA-related genes in schizophrenia: illness progression vs developmental disturbance. ( Bazmi, HH; Hoftman, GD; Lewis, DA; Li, S; Sampson, AR; Volk, DW, 2015)
"A patient with Usher syndrome and psychiatric symptoms is described and the difficulties in psychiatric assessment in her case are discussed."1.35Usher syndrome and psychiatric symptoms: a challenge in psychiatric management. ( Grubic, VN; Rijavec, N, 2009)

Research

Studies (106)

TimeframeStudies, this research(%)All Research%
pre-199015 (14.15)18.7374
1990's11 (10.38)18.2507
2000's17 (16.04)29.6817
2010's40 (37.74)24.3611
2020's23 (21.70)2.80

Authors

AuthorsStudies
Li, W1
Xu, J1
Xiang, Q1
Zhuo, K1
Zhang, Y2
Liu, D1
Li, Y1
Vinckier, F1
Gaillard, R1
Taylor, G1
Murray, GK1
Plaze, M1
Bourdillon, P1
Perin-Dureau, F1
Simmonite, M2
Steeby, CJ1
Taylor, SF4
Zahid, U1
Onwordi, EC1
Hedges, EP1
Wall, MB1
Modinos, G3
Murray, RM1
Egerton, A2
Yao, B1
Welsh, RC2
Chen, X1
Song, X1
Öngür, D1
Du, F1
Mancini, V1
Saleh, MG1
Delavari, F1
Bagautdinova, J1
Eliez, S1
Mishra, BR1
Biswas, T1
Sreeraj, VS1
Nath, S1
Mohapatra, D1
Maiti, R1
Bojesen, KB4
Ebdrup, BH1
Jessen, K2
Sigvard, A2
Tangmose, K2
Edden, RAE4
Larsson, HBW2
Rostrup, E5
Broberg, BV5
Glenthøj, BY5
Wenneberg, C3
Hjorthøj, C3
Buchardt Zingenberg, FJ1
Glenthøj, LB3
Nordentoft, M3
Fagerlund, B3
Krakauer, K2
Kristensen, TD2
Schwartz, C1
Uçar, H1
Gundogmus, İ1
Bolu, A1
Çelik, C1
Kegeles, LS2
de la Fuente-Sandoval, C4
Wang, YM1
Xiao, YH1
Xie, WL1
Sydnor, VJ1
Roalf, DR1
Thomas, MB1
Nielsen, MØ1
Andersen, GS1
Heinze, K1
Barron, HC1
Howes, EK1
Ramaswami, M1
Broome, MR2
Colijn, MA1
Sonnenschein, SF1
Grace, A1
Quiñones, GM1
Mayeli, A1
Yushmanov, VE1
Hetherington, HP1
Ferrarelli, F1
Loureiro, CM1
da Roza, DL1
Corsi-Zuelli, F1
Shuhama, R1
Fachim, HA1
Simões-Ambrosio, LMC1
Deminice, R1
Jordão, AA1
Menezes, PR1
Del-Ben, CM1
Louzada-Junior, P1
Reid, MA3
Yadav, M4
Jindal, DK4
Dhingra, MS1
Kumar, A2
Parle, M4
Dhingra, S3
Włodarczyk, A1
Szarmach, J1
Cubała, WJ1
Wiglusz, MS1
Simsek, F2
Horder, J1
Bossong, M2
Bonoldi, I2
Azis, M2
Perez, J2
Broome, M1
Lythgoe, DJ2
Stone, JM3
Howes, OD2
Murphy, DG1
Grace, AA2
Allen, P2
McGuire, P2
Reyes-Madrigal, F2
Mao, X2
León-Ortiz, P2
Rodríguez-Mayoral, O2
Jung-Cook, H1
Solís-Vivanco, R2
Graff-Guerrero, A2
Shungu, DC2
Sharma, N1
Salibi, N2
White, DM2
Gawne, TJ2
Denney, TS1
Lahti, AC2
Rowland, LM1
Wijtenburg, SA1
Samson, C1
Quinn, B1
Zelaya, F1
Ford, TC1
Abu-Akel, A1
Crewther, DP1
Da Silva, T1
Hafizi, S1
Rusjan, PM1
Houle, S1
Wilson, AA1
Prce, I1
Sailasuta, N1
Mizrahi, R1
Koshiyama, D1
Kirihara, K1
Tada, M1
Nagai, T1
Fujioka, M1
Ichikawa, E1
Ohta, K1
Tani, M1
Tsuchiya, M1
Kanehara, A1
Morita, K1
Sawada, K1
Matsuoka, J1
Satomura, Y1
Koike, S1
Suga, M1
Araki, T1
Kasai, K1
Overbeek, G1
Kraguljac, NV1
Wang, AM1
Pradhan, S2
Coughlin, JM1
Trivedi, A1
DuBois, SL1
Crawford, JL1
Sedlak, TW1
Nucifora, FC1
Nestadt, G1
Nucifora, LG1
Schretlen, DJ1
Sawa, A1
Barker, PB2
Grove, TB1
Ellingrod, VL1
Tso, IF2
Demeter, E1
Phan, KL1
Zamberletti, E1
Beggiato, S1
Steardo, L1
Prini, P1
Antonelli, T1
Ferraro, L1
Rubino, T1
Parolaro, D1
Hoftman, GD1
Volk, DW2
Bazmi, HH1
Li, S1
Sampson, AR2
Lewis, DA2
Radhakrishnan, R1
Skosnik, PD1
Cortes-Briones, J1
Sewell, RA1
Carbuto, M1
Schnakenberg, A1
Cahill, J1
Bois, F1
Gunduz-Bruce, H2
Pittman, B2
Ranganathan, M2
D'Souza, DC2
Ahn, KH1
Sewell, A1
Elander, J1
Krystal, J1
Powell, SB1
Khan, A1
Young, JW1
Scott, CN1
Buell, MR1
Caldwell, S1
Tsan, E1
de Jong, LA1
Acheson, DT1
Lucero, J1
Geyer, MA1
Behrens, MM1
Favila, R1
Marenco, S2
Meyer, C1
Kuo, S1
van der Veen, JW1
Shen, J1
DeJong, K1
Barnett, AS1
Apud, JA1
Dickinson, D1
Weinberger, DR1
Berman, KF1
McNally, JM1
McCarley, RW1
Brandt, AS1
Unschuld, PG1
Lim, IA1
Churchill, G1
Harris, AD1
Hua, J1
Ross, CA1
van Zijl, PC1
Edden, RA1
Margolis, RL1
Walther, S1
Strik, W1
Edelson, JR1
Ustohal, L1
Mayerova, M1
Hublova, V1
Prikrylova Kucerova, H1
Ceskova, E1
Kasparek, T1
Wearne, TA1
Parker, LM1
Franklin, JL1
Goodchild, AK1
Cornish, JL1
Uhlhaas, PJ1
Gajwani, R1
Gross, J1
Gumley, AI1
Lawrie, SM1
Schwannauer, M1
Orhan, F1
Fatouros-Bergman, H1
Goiny, M1
Malmqvist, A1
Piehl, F1
Cervenka, S1
Collste, K1
Victorsson, P1
Sellgren, CM1
Flyckt, L1
Erhardt, S1
Engberg, G1
Meyer, U1
Feldon, J1
Rijavec, N1
Grubic, VN1
Iizuka, T1
Hara, A1
Benes, FM1
Kaufman, KR1
Struck, PJ1
Wu, B1
Wong, S1
Sotoing Taïwe, G1
Ngo Bum, E1
Talla, E1
Dawe, A1
Okomolo Moto, FC1
Temkou Ngoupaye, G1
Sidiki, N1
Dabole, B1
Djomeni Dzeufiet, PD1
Dimo, T1
De Waard, M1
Palaniyappan, L1
White, TP1
Liddle, PF1
Hardoy, MC3
Carta, MG3
Carpiniello, B1
Cianchetti, C1
Congia, S1
D'Errico, I1
Emanuelli, G1
Garonna, F1
Hardoy, MJ3
Nardini, M1
Kalkman, HO1
Loetscher, E1
FEITELEVICH, J1
ZIPILIVAN, M1
MORRONI, OB1
Dhossche, DM1
Philippe, A1
Deron, J1
Geneviève, D1
de Lonlay, P1
Gibson, KM1
Rabier, D1
Munnich, A1
Verhoeven, WM1
Tuinier, S1
Tueting, P1
Doueiri, MS1
Guidotti, A1
Davis, JM1
Costa, E1
Brummelte, S1
Neddens, J1
Teuchert-Noodt, G1
Pilc, A1
Ossowska, K1
Sachdev, PS1
Braun, I1
Genius, J1
Grunze, H1
Bender, A1
Möller, HJ1
Rujescu, D1
Huang, M1
Li, Z1
Dai, J1
Shahid, M1
Wong, EH1
Meltzer, HY3
Logothetis, J1
Paraschos, A1
Frangos, E1
Bowers, MB3
Heninger, GR1
Sternberg, D1
Post, RM1
Sheard, MH1
Meldrum, B1
Arora, RC1
Metz, J1
Enna, SJ1
Gold, BI2
Roth, RH2
van Kammen, DP1
Sternberg, DE1
Hare, TA1
Waters, RN1
Bunney, WE1
Sweeney, DW1
Sabatino, M1
Cannizzaro, C1
Flugy, A1
Gagliand, M1
Mineo, A1
Cannizzaro, G1
Devor, EJ1
Waziri, R1
Veggiotti, P2
De Agostini, G2
Baldi, PL2
Muzio, C2
Lanzi, G2
Busatto, GF1
Kerwin, RW1
Termine, C1
Ferrari Ginevra, O1
Cabras, PL2
Letterman, L1
Markowitz, JS1
Keverne, EB1
Krishnamoorthy, ES1
Trimble, MR1
Casey, DE1
Bennett, J1
Goldman, WT1
Suppes, T1
Megna, JL1
Devitt, PJ1
Sauro, MD1
Dewan, MJ1
Bourne, JA1
Costentin, J1
Gerlach, J1
Gillman, MA1
Lichtigfeld, FJ1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomised Clinical Trial Examining Cognitive Remediation Plus Standard Treatment Versus Standard Treatment in Participants at Ultra-High Risk of Psychosis. - Effect on Cognitive Functioning, Functional Outcome and Symptomatology.[NCT02098408]146 participants (Actual)Interventional2014-03-31Completed
Pan European Collaboration on Antipsychotic Naïve Schizophrenia II[NCT02339844]Phase 4130 participants (Actual)Interventional2014-01-31Completed
Evaluation of Schemes of Administration of Intravenous Ketamine in Treatment-resistant Depression: Clinical-neuroimaging Correlation[NCT03742557]Phase 330 participants (Anticipated)Interventional2018-10-01Recruiting
The Relationship Between the Efficacy of Lumateperone and Central Glutamate and Dopaminergic Metabolism: A Comparison With Risperidone in First Episode Psychosis[NCT05890768]Phase 435 participants (Anticipated)Interventional2023-05-11Recruiting
Use of Electroconvulsive Therapy to Treat Self-Injurious Behavior in Adults With Autism Spectrum Disorders[NCT03980366]1 participants (Actual)Interventional2019-03-15Terminated (stopped due to We have not obtained additional subjects and chose to terminate/close this study.)
Combined PET and MR Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 1: Simultaneous PET and 3T MRI[NCT05232955]40 participants (Anticipated)Observational2022-02-28Not yet recruiting
Combined PET and MR Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 2: 7T MRI[NCT05233306]60 participants (Anticipated)Observational2022-01-27Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

31 reviews available for gamma-aminobutyric acid and Psychotic Disorders

ArticleYear
Medial Frontal Cortex GABA Concentrations in Psychosis Spectrum and Mood Disorders: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies.
    Biological psychiatry, 2023, 01-15, Volume: 93, Issue:2

    Topics: Frontal Lobe; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Mood Disorders; Proton Magnetic Resona

2023
Neurofunctional correlates of glutamate and GABA imbalance in psychosis: A systematic review.
    Neuroscience and biobehavioral reviews, 2023, Volume: 144

    Topics: gamma-Aminobutyric Acid; Glutamic Acid; Humans; Magnetic Resonance Imaging; Psychotic Disorders; Sch

2023
Paroxysmal dystonia and psychotic exacerbations in chronic psychosis: Diagnostic dilemmas and preliminary treatment approaches.
    British journal of clinical pharmacology, 2023, Volume: 89, Issue:9

    Topics: Antipsychotic Agents; Clozapine; Dystonia; gamma-Aminobutyric Acid; Humans; Psychotic Disorders

2023
Cerebral glutamate and GABA levels in high-risk of psychosis states: A focused review and meta-analysis of
    Schizophrenia research, 2020, Volume: 215

    Topics: Frontal Lobe; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Prodromal Symptoms; Proton Magnetic Re

2020
Metabolite abnormalities in psychosis risk: A meta-analysis of proton magnetic resonance spectroscopy studies.
    Asian journal of psychiatry, 2020, Volume: 54

    Topics: gamma-Aminobutyric Acid; Glutamic Acid; Humans; Proton Magnetic Resonance Spectroscopy; Psychotic Di

2020
A meta-analysis of ultra-high field glutamate, glutamine, GABA and glutathione 1HMRS in psychosis: Implications for studies of psychosis risk.
    Schizophrenia research, 2020, Volume: 226

    Topics: Adolescent; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Glutathione; Humans; Psychotic Disord

2020
Impaired inhibitory processing: a new therapeutic target for autism and psychosis?
    The British journal of psychiatry : the journal of mental science, 2021, Volume: 218, Issue:6

    Topics: Autism Spectrum Disorder; Autistic Disorder; Brain; gamma-Aminobutyric Acid; Humans; Inhibition, Psy

2021
The characterization of psychotic symptoms in succinic semialdehyde dehydrogenase deficiency: a review.
    Psychiatric genetics, 2020, Volume: 30, Issue:6

    Topics: Adolescent; Age of Onset; Aggression; Amino Acid Metabolism, Inborn Errors; Anticonvulsants; Anxiety

2020
Emerging therapeutic targets for schizophrenia: a framework for novel treatment strategies for psychosis.
    Expert opinion on therapeutic targets, 2021, Volume: 25, Issue:1

    Topics: Animals; Antipsychotic Agents; Dopamine; Drug Design; gamma-Aminobutyric Acid; Glutamates; Hippocamp

2021
The Fragile Brain: Stress Vulnerability, Negative Affect and GABAergic Neurocircuits in Psychosis.
    Schizophrenia bulletin, 2019, 10-24, Volume: 45, Issue:6

    Topics: Affect; Amygdala; Animals; Brain; Disease Models, Animal; gamma-Aminobutyric Acid; Hippocampus; Huma

2019
Gamma band oscillations: a key to understanding schizophrenia symptoms and neural circuit abnormalities.
    Current opinion in psychiatry, 2016, Volume: 29, Issue:3

    Topics: Animals; Cognition Disorders; gamma-Aminobutyric Acid; Humans; Neurons; Parvalbumins; Psychotic Diso

2016
Catatonia.
    CNS spectrums, 2016, Volume: 21, Issue:4

    Topics: Benzodiazepines; Catatonia; Diagnostic and Statistical Manual of Mental Disorders; Electroconvulsive

2016
[Anti-NMDA receptor antibody-mediated encephalitis/encephalopathy].
    Rinsho byori. The Japanese journal of clinical pathology, 2009, Volume: 57, Issue:3

    Topics: Autoantibodies; Dyskinesias; Epitopes; Female; gamma-Aminobutyric Acid; Glutamates; Humans; Limbic E

2009
Regulation of cell cycle and DNA repair in post-mitotic GABA neurons in psychotic disorders.
    Neuropharmacology, 2011, Volume: 60, Issue:7-8

    Topics: Adult; Cell Cycle; DNA Repair; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Humans; Neurons; Ps

2011
The glutamate hypothesis of schizophrenia: neuroimaging and drug development.
    Current pharmaceutical biotechnology, 2012, Volume: 13, Issue:8

    Topics: Animals; Diagnostic Imaging; Drug Design; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Psychotic

2012
The concept of salience network dysfunction in schizophrenia: from neuroimaging observations to therapeutic opportunities.
    Current topics in medicinal chemistry, 2012, Volume: 12, Issue:21

    Topics: Cerebral Cortex; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Gyrus Cinguli; Humans; Magnetic R

2012
GAD(67): the link between the GABA-deficit hypothesis and the dopaminergic- and glutamatergic theories of psychosis.
    Journal of neural transmission (Vienna, Austria : 1996), 2003, Volume: 110, Issue:7

    Topics: Animals; Brain; Dopamine; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Glutamine; Humans; Isoen

2003
Autism as early expression of catatonia.
    Medical science monitor : international medical journal of experimental and clinical research, 2004, Volume: 10, Issue:3

    Topics: Adolescent; Age of Onset; Autistic Disorder; Catatonia; Cerebellum; Child; gamma-Aminobutyric Acid;

2004
Prader-Willi syndrome: atypical psychoses and motor dysfunctions.
    International review of neurobiology, 2006, Volume: 72

    Topics: Adolescent; Adult; Female; gamma-Aminobutyric Acid; Humans; Male; Prader-Willi Syndrome; Psychomotor

2006
Reelin down-regulation in mice and psychosis endophenotypes.
    Neuroscience and biobehavioral reviews, 2006, Volume: 30, Issue:8

    Topics: Animals; Behavior, Animal; Brain; Cell Adhesion Molecules, Neuronal; Disease Models, Animal; Down-Re

2006
Alternating and postictal psychoses: review and a unifying hypothesis.
    Schizophrenia bulletin, 2007, Volume: 33, Issue:4

    Topics: Brain; Electroencephalography; Epilepsy; gamma-Aminobutyric Acid; Humans; N-Methylaspartate; Psychot

2007
Use of the anticonvulsant carbamazepine in primary and secondary affective illness: clinical and theoretical implications.
    Psychological medicine, 1982, Volume: 12, Issue:4

    Topics: Affective Disorders, Psychotic; Animals; Antidepressive Agents; Antipsychotic Agents; Bipolar Disord

1982
Clinical pharmacology of aggressive behavior.
    Clinical neuropharmacology, 1984, Volume: 7, Issue:3

    Topics: Adolescent; Adult; Aged; Aggression; Anger; Anti-Anxiety Agents; Benzodiazepines; Brain Chemistry; C

1984
GABA and acute psychoses.
    Psychological medicine, 1982, Volume: 12, Issue:1

    Topics: Acute Disease; Animals; Brain; Cats; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Humans; Limbi

1982
Schizophrenia, psychosis, and the basal ganglia.
    The Psychiatric clinics of North America, 1997, Volume: 20, Issue:4

    Topics: Antipsychotic Agents; Basal Ganglia; Behavioral Symptoms; gamma-Aminobutyric Acid; Humans; Neuropsyc

1997
Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions.
    Pharmacotherapy, 1999, Volume: 19, Issue:5

    Topics: Acetates; Amines; Anticonvulsants; Anxiety; Bipolar Disorder; Cyclohexanecarboxylic Acids; Gabapenti

1999
GABA-ergic neurons and the neurobiology of schizophrenia and other psychoses.
    Brain research bulletin, 1999, Mar-15, Volume: 48, Issue:5

    Topics: Animals; Cerebral Cortex; gamma-Aminobutyric Acid; Humans; Interneurons; Psychoses, Substance-Induce

1999
Forced normalization: clinical and therapeutic relevance.
    Epilepsia, 1999, Volume: 40 Suppl 10

    Topics: Animals; Cats; Cerebral Cortex; Comorbidity; Diagnosis, Differential; Dopamine; Electroencephalograp

1999
Tardive dyskinesia: pathophysiology and animal models.
    The Journal of clinical psychiatry, 2000, Volume: 61 Suppl 4

    Topics: Age Factors; Animals; Antipsychotic Agents; Basal Ganglia; Behavior, Animal; Disease Models, Animal;

2000
SCH 23390: the first selective dopamine D1-like receptor antagonist.
    CNS drug reviews, 2001,Winter, Volume: 7, Issue:4

    Topics: Animals; Anticonvulsants; Antipsychotic Agents; Behavior, Animal; Benzazepines; Brain; Dopamine; Dop

2001
SCH 23390: the first selective dopamine D1-like receptor antagonist.
    CNS drug reviews, 2001,Winter, Volume: 7, Issue:4

    Topics: Animals; Anticonvulsants; Antipsychotic Agents; Behavior, Animal; Benzazepines; Brain; Dopamine; Dop

2001
SCH 23390: the first selective dopamine D1-like receptor antagonist.
    CNS drug reviews, 2001,Winter, Volume: 7, Issue:4

    Topics: Animals; Anticonvulsants; Antipsychotic Agents; Behavior, Animal; Benzazepines; Brain; Dopamine; Dop

2001
SCH 23390: the first selective dopamine D1-like receptor antagonist.
    CNS drug reviews, 2001,Winter, Volume: 7, Issue:4

    Topics: Animals; Anticonvulsants; Antipsychotic Agents; Behavior, Animal; Benzazepines; Brain; Dopamine; Dop

2001
[Modulation of dopaminergic receptor sensitivity in the central nervous system: important parameters in synaptic function regulation].
    L'Encephale, 1979, Volume: 5, Issue:2

    Topics: Acetylcholine; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Behavior; Corpus Stria

1979

Trials

8 trials available for gamma-aminobutyric acid and Psychotic Disorders

ArticleYear
Abnormal GABAergic function and negative affect in schizophrenia.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2014, Volume: 39, Issue:4

    Topics: Adult; Cerebral Cortex; Cross-Over Studies; Female; GABA Modulators; gamma-Aminobutyric Acid; Humans

2014
GABA Deficits Enhance the Psychotomimetic Effects of Δ9-THC.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015, Volume: 40, Issue:8

    Topics: Adolescent; Adult; Brain Mapping; Dissociative Disorders; Double-Blind Method; Dronabinol; Electroen

2015
Role of GABA Deficit in Sensitivity to the Psychotomimetic Effects of Amphetamine.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015, Volume: 40, Issue:12

    Topics: Adolescent; Adult; Amphetamine; Cross-Over Studies; Double-Blind Method; Drug Administration Schedul

2015
Gabapentin in antipsychotic-induced tardive dyskinesia: results of 1-year follow-up.
    Journal of affective disorders, 2003, Volume: 75, Issue:2

    Topics: Acetates; Adult; Amines; Anticonvulsants; Antipsychotic Agents; Cyclohexanecarboxylic Acids; Dyskine

2003
Use of the anticonvulsant carbamazepine in primary and secondary affective illness: clinical and theoretical implications.
    Psychological medicine, 1982, Volume: 12, Issue:4

    Topics: Affective Disorders, Psychotic; Animals; Antidepressive Agents; Antipsychotic Agents; Bipolar Disord

1982
Vigabatrin use in psychotic epileptic patients: report of a prospective pilot study.
    Acta neurologica Scandinavica, 1999, Volume: 99, Issue:3

    Topics: Adolescent; Adult; Anticonvulsants; Behavioral Symptoms; Child; Child, Preschool; Drug Administratio

1999
Clinical experience with gabapentin in patients with bipolar or schizoaffective disorder: results of an open-label study.
    The Journal of clinical psychiatry, 1999, Volume: 60, Issue:4

    Topics: Acetates; Acute Disease; Adult; Aged; Amines; Anticonvulsants; Antimanic Agents; Antipsychotic Agent

1999
Gabapentin's effect on agitation in severely and persistently mentally ill patients.
    The Annals of pharmacotherapy, 2002, Volume: 36, Issue:1

    Topics: Acetates; Amines; Antimanic Agents; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobuty

2002

Other Studies

68 other studies available for gamma-aminobutyric acid and Psychotic Disorders

ArticleYear
Neurometabolic and functional changes of default-mode network relate to clinical recovery in first-episode psychosis patients: A longitudinal
    NeuroImage. Clinical, 2022, Volume: 34

    Topics: Antipsychotic Agents; Aspartic Acid; Brain; Brain Mapping; Default Mode Network; gamma-Aminobutyric

2022
Acute psychosis following propofol in a patient with Parkinson disease: Effects of a γ-aminobutyric acid-dopamine imbalance.
    Psychiatry and clinical neurosciences, 2022, Volume: 76, Issue:6

    Topics: Anesthetics, Intravenous; Dopamine; gamma-Aminobutyric Acid; Humans; Parkinson Disease; Propofol; Ps

2022
Increased rostral medial frontal GABA+ in early psychosis is obscured by levels of negative affect.
    Schizophrenia research, 2023, Volume: 252

    Topics: Affect; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Psychotic Disorders; Schizophrenia

2023
Association of default-mode network neurotransmitters and inter-network functional connectivity in first episode psychosis.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2023, Volume: 48, Issue:5

    Topics: Brain; Brain Mapping; Default Mode Network; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Magnetic

2023
Excitatory/Inhibitory Imbalance Underlies Hippocampal Atrophy in Individuals With 22q11.2 Deletion Syndrome With Psychotic Symptoms.
    Biological psychiatry, 2023, 10-01, Volume: 94, Issue:7

    Topics: Atrophy; DiGeorge Syndrome; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Hippocampus; Humans;

2023
Treatment response after 6 and 26 weeks is related to baseline glutamate and GABA levels in antipsychotic-naïve patients with psychosis.
    Psychological medicine, 2020, Volume: 50, Issue:13

    Topics: Adolescent; Adult; Antipsychotic Agents; Case-Control Studies; Female; gamma-Aminobutyric Acid; Glut

2020
Cerebral Glutamate and Gamma-Aminobutyric Acid Levels in Individuals at Ultra-high Risk for Psychosis and the Association With Clinical Symptoms and Cognition.
    Biological psychiatry. Cognitive neuroscience and neuroimaging, 2020, Volume: 5, Issue:6

    Topics: Cognition; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Humans; Psychotic Disorders

2020
Transient Psychosis After Low-Dose Pregabalin Discontinuation.
    American journal of therapeutics, 2022, 07-01, Volume: 29, Issue:4

    Topics: Analgesics; Anticonvulsants; gamma-Aminobutyric Acid; Humans; Pregabalin; Psychotic Disorders

2022
Gamma-Aminobutyric Acid, Glutamate, and Cognition in Early Stages of Psychosis: Are We Closing the Gap?
    Biological psychiatry. Cognitive neuroscience and neuroimaging, 2020, Volume: 5, Issue:6

    Topics: Cognition; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Psychotic Disorders

2020
Baseline measures of cerebral glutamate and GABA levels in individuals at ultrahigh risk for psychosis: Implications for clinical outcome after 12 months.
    European psychiatry : the journal of the Association of European Psychiatrists, 2020, 08-07, Volume: 63, Issue:1

    Topics: Adolescent; Adult; Brain Chemistry; Cognition; Cognitive Dysfunction; gamma-Aminobutyric Acid; Gluta

2020
Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naïve Patients With Schizophrenia or Psychosis.
    Biological psychiatry, 2021, 02-01, Volume: 89, Issue:3

    Topics: Antipsychotic Agents; Cognition; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Gyrus Cinguli; H

2021
Reduced GABA/glutamate in the thalamus of individuals at clinical high risk for psychosis.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2021, Volume: 46, Issue:6

    Topics: Adolescent; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Magnetic Resonance Imaging; Psychotic Di

2021
Plasma amino acids profile in first-episode psychosis, unaffected siblings and community-based controls.
    Scientific reports, 2020, 12-08, Volume: 10, Issue:1

    Topics: Adult; Amino Acids; Antipsychotic Agents; Body Mass Index; Case-Control Studies; Cross-Sectional Stu

2020
Glutamate and Gamma-Aminobutyric Acid Abnormalities in Antipsychotic-Naïve Patients With Schizophrenia: Evidence From Empirical and Meta-analytic Studies Using Magnetic Resonance Spectroscopy.
    Biological psychiatry, 2021, 02-01, Volume: 89, Issue:3

    Topics: Antipsychotic Agents; Cognition; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Magnetic Resonance

2021
Protective effect of gallic acid in experimental model of ketamine-induced psychosis: possible behaviour, biochemical, neurochemical and cellular alterations.
    Inflammopharmacology, 2018, Volume: 26, Issue:2

    Topics: Animals; Antioxidants; Behavior, Animal; Brain; Disease Models, Animal; Female; Gallic Acid; gamma-A

2018
Benzodiazepines in combination with antipsychotic drugs for schizophrenia: GABA-ergic targeted therapy.
    Psychiatria Danubina, 2017, Volume: 29, Issue:Suppl 3

    Topics: Antipsychotic Agents; Benzodiazepines; gamma-Aminobutyric Acid; Humans; Psychotic Disorders; Schizop

2017
Cortical GABA in Subjects at Ultra-High Risk of Psychosis: Relationship to Negative Prodromal Symptoms.
    The international journal of neuropsychopharmacology, 2018, 02-01, Volume: 21, Issue:2

    Topics: Adolescent; Adult; gamma-Aminobutyric Acid; Humans; Male; Prefrontal Cortex; Prodromal Symptoms; Pro

2018
Prefrontal and Striatal Gamma-Aminobutyric Acid Levels and the Effect of Antipsychotic Treatment in First-Episode Psychosis Patients.
    Biological psychiatry, 2018, 03-15, Volume: 83, Issue:6

    Topics: Adolescent; Adult; Antipsychotic Agents; Aspartic Acid; Corpus Striatum; Female; gamma-Aminobutyric

2018
Potential effect of spermidine on GABA, dopamine, acetylcholinesterase, oxidative stress and proinflammatory cytokines to diminish ketamine-induced psychotic symptoms in rats.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 98

    Topics: Acetylcholinesterase; Animals; Antipsychotic Agents; Brain; Cytokines; Dopamine; Female; gamma-Amino

2018
7T Proton Magnetic Resonance Spectroscopy of the Anterior Cingulate Cortex in First-Episode Schizophrenia.
    Schizophrenia bulletin, 2019, 01-01, Volume: 45, Issue:1

    Topics: Adult; Aspartic Acid; Cognitive Dysfunction; Female; gamma-Aminobutyric Acid; Glutamic Acid; Gyrus C

2019
Magnetic Resonance Spectroscopy Gamma-Aminobutyric Acid: A Promising Biomarker for Antipsychotic Treatment?
    Biological psychiatry, 2018, 03-15, Volume: 83, Issue:6

    Topics: Antipsychotic Agents; Biomarkers; gamma-Aminobutyric Acid; Humans; Magnetic Resonance Spectroscopy;

2018
Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosis.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2018, Volume: 43, Issue:13

    Topics: Adolescent; Adult; Biomarkers; Female; gamma-Aminobutyric Acid; Hippocampus; Humans; Magnetic Resona

2018
Targeting oxidative stress, acetylcholinesterase, proinflammatory cytokine, dopamine and GABA by eucalyptus oil (Eucalyptus globulus) to alleviate ketamine-induced psychosis in rats.
    Inflammopharmacology, 2019, Volume: 27, Issue:2

    Topics: Acetylcholinesterase; Animals; Cytokines; Dopamine; Eucalyptus; Eucalyptus Oil; gamma-Aminobutyric A

2019
Protective effects of stigmasterol against ketamine-induced psychotic symptoms: Possible behavioral, biochemical and histopathological changes in mice.
    Pharmacological reports : PR, 2018, Volume: 70, Issue:3

    Topics: Acetylcholine; Animals; Antipsychotic Agents; Brain; Catalepsy; Disease Models, Animal; Dopamine; ga

2018
The association of excitation and inhibition signaling with the relative symptom expression of autism and psychosis-proneness: Implications for psychopharmacology.
    Progress in neuro-psychopharmacology & biological psychiatry, 2019, 01-10, Volume: 88

    Topics: Adolescent; Adult; Autistic Disorder; Female; Follow-Up Studies; Functional Laterality; gamma-Aminob

2019
GABA levels and TSPO expression in people at clinical high risk for psychosis and healthy volunteers: a PET-MRS study.
    Journal of psychiatry & neuroscience : JPN, 2019, 03-01, Volume: 44, Issue:2

    Topics: Adolescent; Adult; Anilides; Cross-Sectional Studies; Female; gamma-Aminobutyric Acid; Humans; Male;

2019
Electrophysiological evidence for abnormal glutamate-GABA association following psychosis onset.
    Translational psychiatry, 2018, 10-08, Volume: 8, Issue:1

    Topics: Acoustic Stimulation; Adult; Brain; Electroencephalography; Evoked Potentials, Auditory; Female; Gam

2018
Relationship Between Cortical Excitation and Inhibition and Task-Induced Activation and Deactivation: A Combined Magnetic Resonance Spectroscopy and Functional Magnetic Resonance Imaging Study at 7T in First-Episode Psychosis.
    Biological psychiatry. Cognitive neuroscience and neuroimaging, 2019, Volume: 4, Issue:2

    Topics: Adult; Brain; Cortical Excitability; Female; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Magneti

2019
Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.
    JAMA psychiatry, 2019, 03-01, Volume: 76, Issue:3

    Topics: Aspartic Acid; Brain; Case-Control Studies; Cross-Sectional Studies; Dipeptides; Female; gamma-Amino

2019
Alterations of prefrontal cortex GABAergic transmission in the complex psychotic-like phenotype induced by adolescent delta-9-tetrahydrocannabinol exposure in rats.
    Neurobiology of disease, 2014, Volume: 63

    Topics: Age Factors; Animals; Animals, Newborn; Cannabinoid Receptor Agonists; Disease Models, Animal; Dose-

2014
Altered cortical expression of GABA-related genes in schizophrenia: illness progression vs developmental disturbance.
    Schizophrenia bulletin, 2015, Volume: 41, Issue:1

    Topics: Adult; Animals; Calbindin 2; Case-Control Studies; Disease Progression; Female; GABA Plasma Membrane

2015
Early Adolescent Emergence of Reversal Learning Impairments in Isolation-Reared Rats.
    Developmental neuroscience, 2015, Volume: 37, Issue:3

    Topics: Age Factors; Animals; Behavior, Animal; Cognition Disorders; Disease Models, Animal; Female; gamma-A

2015
Cortico-Striatal GABAergic and Glutamatergic Dysregulations in Subjects at Ultra-High Risk for Psychosis Investigated with Proton Magnetic Resonance Spectroscopy.
    The international journal of neuropsychopharmacology, 2015, Sep-12, Volume: 19, Issue:3

    Topics: Corpus Striatum; Female; gamma-Aminobutyric Acid; Genetic Predisposition to Disease; Glutamic Acid;

2015
Prefrontal GABA Levels Measured With Magnetic Resonance Spectroscopy in Patients With Psychosis and Unaffected Siblings.
    The American journal of psychiatry, 2016, 05-01, Volume: 173, Issue:5

    Topics: Adult; Antipsychotic Agents; Case-Control Studies; Female; gamma-Aminobutyric Acid; Gyrus Cinguli; H

2016
Age-related changes in anterior cingulate cortex glutamate in schizophrenia: A (1)H MRS Study at 7 Tesla.
    Schizophrenia research, 2016, Volume: 172, Issue:1-3

    Topics: Adult; Aging; Antipsychotic Agents; Aspartic Acid; Choline; Creatine; Dipeptides; Female; gamma-Amin

2016
Brain GABA Function and Psychosis.
    The American journal of psychiatry, 2016, 05-01, Volume: 173, Issue:5

    Topics: Brain; gamma-Aminobutyric Acid; Humans; Psychotic Disorders

2016
Cortical GABA markers identify a molecular subtype of psychotic and bipolar disorders.
    Psychological medicine, 2016, Volume: 46, Issue:12

    Topics: Adult; Biomarkers; Bipolar Disorder; Female; GABAergic Neurons; gamma-Aminobutyric Acid; Glutamate D

2016
Response to de la Fuente-Sandoval: Challenges Measuring GABA Levels in Patients With Psychosis.
    The American journal of psychiatry, 2016, 07-01, Volume: 173, Issue:7

    Topics: gamma-Aminobutyric Acid; Humans; Psychotic Disorders

2016
Potential Regional Differences in GABA Levels in Patients With Psychosis Compared With Control Subjects.
    The American journal of psychiatry, 2016, 07-01, Volume: 173, Issue:7

    Topics: gamma-Aminobutyric Acid; Humans; Psychotic Disorders; Schizophrenia

2016
Risperidone increases the cortical silent period in drug-naive patients with first-episode schizophrenia: A transcranial magnetic stimulation study.
    Journal of psychopharmacology (Oxford, England), 2017, Volume: 31, Issue:4

    Topics: Adult; Antipsychotic Agents; Cerebral Cortex; gamma-Aminobutyric Acid; Humans; Neural Inhibition; Ps

2017
GABAergic mRNA expression is differentially expressed across the prelimbic and orbitofrontal cortices of rats sensitized to methamphetamine: Relevance to psychosis.
    Neuropharmacology, 2016, Volume: 111

    Topics: Animals; GABA Plasma Membrane Transport Proteins; gamma-Aminobutyric Acid; Glutamate Decarboxylase;

2016
The Youth Mental Health Risk and Resilience Study (YouR-Study).
    BMC psychiatry, 2017, 01-26, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Biomarkers; Brain; Clinical Protocols; Early Diagnosis; Female; gamma-Aminobutyri

2017
CSF GABA is reduced in first-episode psychosis and associates to symptom severity.
    Molecular psychiatry, 2018, Volume: 23, Issue:5

    Topics: Adult; Antipsychotic Agents; Brain; Case-Control Studies; Chromatography, High Pressure Liquid; Fema

2018
Neural basis of psychosis-related behaviour in the infection model of schizophrenia.
    Behavioural brain research, 2009, Dec-07, Volume: 204, Issue:2

    Topics: Animals; Avoidance Learning; Brain; Disease Models, Animal; Dopamine; Female; gamma-Aminobutyric Aci

2009
Usher syndrome and psychiatric symptoms: a challenge in psychiatric management.
    Psychiatria Danubina, 2009, Volume: 21, Issue:1

    Topics: Adult; Anorexia Nervosa; Anti-Anxiety Agents; Antipsychotic Agents; Clozapine; Comorbidity; Diagnosi

2009
Off-label gabapentin masking ictal triphasic waves: case analysis of neuropsychiatric and electrographic correlates.
    Epilepsy & behavior : E&B, 2011, Volume: 22, Issue:3

    Topics: Administration, Oral; Aged; Amines; Anticonvulsants; Brain Waves; Cyclohexanecarboxylic Acids; Elect

2011
Antipsychotic and sedative effects of the leaf extract of Crassocephalum bauchiense (Hutch.) Milne-Redh (Asteraceae) in rodents.
    Journal of ethnopharmacology, 2012, Aug-30, Volume: 143, Issue:1

    Topics: Animals; Antipsychotic Agents; Apomorphine; Asteraceae; Behavior, Animal; Body Temperature; Brain; C

2012
[Effects of gamma-aminobutyric acid-pyridoxine in presenile and senile psychiatric disorders].
    La Semana medica, 1962, Dec-31, Volume: 121

    Topics: Amino Acids; Dementia; gamma-Aminobutyric Acid; Humans; Mental Disorders; Psychotic Disorders; Pyrid

1962
[IMMEDIATE CLINICAL RESULTS WITH GAMMA AMINOBUTYRIC ACID B6 IN SCHIZOPHRENIAS AND DELIRIUMS].
    La Semana medica, 1963, Sep-16, Volume: 123

    Topics: Aminobutyrates; Biochemical Phenomena; Biochemistry; Delirium; gamma-Aminobutyric Acid; Mental Disor

1963
Neurodevelopmental pattern of succinic semialdehyde dehydrogenase deficiency (gamma-hydroxybutyric aciduria).
    Developmental medicine and child neurology, 2004, Volume: 46, Issue:8

    Topics: Adolescent; Aldehyde Oxidoreductases; Child, Preschool; Developmental Disabilities; gamma-Aminobutyr

2004
Alteration in the GABAergic network of the prefrontal cortex in a potential animal model of psychosis.
    Journal of neural transmission (Vienna, Austria : 1996), 2007, Volume: 114, Issue:5

    Topics: Aging; Animals; Cell Differentiation; Disease Models, Animal; Dopamine Uptake Inhibitors; Environmen

2007
Metabotropic glutamate receptors.
    Amino acids, 2007, Volume: 32, Issue:2

    Topics: Animals; Antipsychotic Agents; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Ligands; Models, Biol

2007
Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism.
    Schizophrenia research, 2007, Volume: 97, Issue:1-3

    Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dizocilpine Maleate; gamma-Aminobutyric Acid;

2007
Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2008, Volume: 33, Issue:12

    Topics: Acetylcholine; Animals; Antipsychotic Agents; Brain Chemistry; Dibenzocycloheptenes; Dopamine; Dose-

2008
Side effects in preventive maintenance therapy with neuroleptics with special emphasis on tardive dyskinesia.
    Bibliotheca psychiatrica, 1981, Issue:160

    Topics: Antipsychotic Agents; Chronic Disease; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Pa

1981
Clinical processes and central dopaminergic activity in psychotic disorders.
    Communications in psychopharmacology, 1980, Volume: 4, Issue:3

    Topics: Adolescent; Adult; Antipsychotic Agents; Dopamine; Female; gamma-Aminobutyric Acid; Homovanillic Aci

1980
Biological studies of schizoaffective disorders.
    Schizophrenia bulletin, 1984, Volume: 10, Issue:1

    Topics: Blood Platelets; Catechol O-Methyltransferase; Dexamethasone; Dopamine; Dopamine beta-Hydroxylase; g

1984
GABA and neuropsychiatric disorders.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1980, Volume: 7, Issue:3

    Topics: Animals; Basal Ganglia; Central Nervous System Diseases; Epilepsies, Myoclonic; Epilepsies, Partial;

1980
CSF GABA in psychotic disorders.
    Psychopharmacology, 1980, Volume: 70, Issue:3

    Topics: Adolescent; Adult; Female; gamma-Aminobutyric Acid; Haloperidol; Homovanillic Acid; Humans; Male; Mi

1980
CSF levels of gamma-aminobutyric acid in schizophrenia. Low values in recently ill patients.
    Archives of general psychiatry, 1982, Volume: 39, Issue:1

    Topics: Adult; Double-Blind Method; Female; gamma-Aminobutyric Acid; Humans; Male; Pimozide; Psychotic Disor

1982
GABA levels in CSF of patients with psychiatric disorders.
    The American journal of psychiatry, 1980, Volume: 137, Issue:3

    Topics: Adult; Aged; Bipolar Disorder; Depression; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Age

1980
NMDA-GABA interactions in an animal model of behaviour: a gating mechanism from motivation toward psychotic-like symptoms.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 1994, Volume: 4, Issue:2

    Topics: Alprazolam; Animals; Behavior, Animal; Desipramine; Disease Models, Animal; Dizocilpine Maleate; gam

1994
A familial/genetic study of plasma serine and glycine concentrations.
    Biological psychiatry, 1993, Aug-15, Volume: 34, Issue:4

    Topics: Dopamine; Female; gamma-Aminobutyric Acid; Glucose; Glutamates; Glycine; Humans; Internal-External C

1993
Vigabatrin and psychosis: is there a true correlation?
    Acta neurologica Scandinavica, 1997, Volume: 95, Issue:3

    Topics: Anticonvulsants; Electroencephalography; Epilepsies, Partial; gamma-Aminobutyric Acid; Humans; Psych

1997
Gabapentin as a promising treatment for antipsychotic-induced movement disorders in schizoaffective and bipolar patients.
    Journal of affective disorders, 1999, Volume: 54, Issue:3

    Topics: Acetates; Adult; Amines; Anti-Anxiety Agents; Antipsychotic Agents; Bipolar Disorder; Cyclohexanecar

1999
Gabapentin for treatment of bipolar and schizoaffective disorders.
    Journal of clinical psychopharmacology, 1997, Volume: 17, Issue:2

    Topics: Acetates; Adult; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Female; Ga

1997
Pathophysiological mechanisms underlying tardive dyskinesia.
    Psychopharmacology. Supplementum, 1985, Volume: 2

    Topics: Antipsychotic Agents; Basal Ganglia Diseases; Brain; Dyskinesia, Drug-Induced; gamma-Aminobutyric Ac

1985
The opioids and the GABA-ergic differentiation of the psychoses.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1986, Feb-01, Volume: 69, Issue:3

    Topics: gamma-Aminobutyric Acid; Humans; Nitrous Oxide; Psychotic Disorders

1986